Article
Multidisciplinary Sciences
Ou Yamaguchi, Kyoichi Kaira, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Kazunari Tateishi, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Ichiei Kuji, Nobuhiko Seki
Summary: This study aimed to investigate the clinical relevance of F-18-FDG PET/CT compared to CT in predicting the response to PD-1 blockade in the early phase. The results showed that metabolic assessment by MTV or TLG was superior to morphological changes on CT for predicting the therapeutic response and survival.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Immunology
Ander Puyalto, Maria Rodriguez-Remirez, Ines Lopez, Fabiola Iribarren, Jon Ander Simon, Marga Ecay, Maria Collantes, Anna Vilalta-Lacarra, Alejandro Francisco-Cruz, Jose Luis Solorzano, Sergio Sandiego, Ivan Penuelas, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Summary: This study demonstrates the use of [Zr-89]-anti-PD-1 immuno-PET as a safe and feasible imaging modality to accurately assess the response to PD-1/PD-L1 blockade in NSCLC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Clemens Hinterleitner, Jasmin Straehle, Elke Malenke, Martina Hinterleitner, Melanie Henning, Marco Seehawer, Tatjana Bilich, Jonas Heitmann, Martina Lutz, Sven Mattern, Sophia Scheuermann, Marius Horger, Stefanie Maurer, Juliane Walz, Falko Fend, Rupert Handgretinger, Christian Seitz, Bettina Weigelin, Stephan Singer, Helmut Salih, Oliver Borst, Hans-Georg Kopp, Lars Zender
Summary: This study demonstrates that platelet-derived PD-L1 can serve as a prognostic and predictive biomarker in non-small cell lung cancer patients, playing a role in tumor immune evasion and affecting T cell function. An algorithm was developed to calculate the adjusted PD-L1 payload of platelets (pPD-L1(Adj.)), which showed superior predictive ability for therapy response compared to standard histological PD-L1 quantification.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, Research & Experimental
Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama
Summary: Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy. However, there are still some problems, including low response rate, resistance against immune checkpoint blockades, and the lack of reliable biomarkers. This study shows that a splicing variant of PD-L1, PD-L1-vInt4, acts as a decoy in anti-PD-L1 antibody treatment, contributing to the resistance of cancer to therapy.
Article
Oncology
Martin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csoszi, Andrea Fulop, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A. Leal, Jonathan W. Riess, Erin Jensen, Bin Zhao, M. Catherine Pietanza, Julie R. Brahmer
Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Beung-Chul Ahn, Charny Park, Sang-Jin Lee, Sehwa Hong, Ji-Eun Hwang, Kyoungsuk Kwon, Jin Young Kim, Kyung-Hee Kim, Hyae Young Kim, Geon Kook Lee, Youngjoo Lee, Ji-Youn Han
Summary: This study investigated the efficacy of cyclophosphamide and adriamycin induction therapy prior to nivolumab in previously treated non-squamous non-small-cell lung cancer patients with low PD-L1 expression. It was found that the induction therapy reduced myeloid-derived suppressor cells and resulted in a durable response. Additionally, higher baseline levels of transferrin receptor protein predicted a favorable response to nivolumab in patients with low PD-L1 expression.
Article
Oncology
Kamya Sankar, Garth W. Strohbehn, Lili Zhao, Victoria Daniel, David Elliott, Nithya Ramnath, Michael D. Green
Summary: Increasing tumor PD-L1 expression is prognostic for progression-free survival (PFS) and overall survival (OS) among patients with stage III non-small cell lung cancer (NSCLC) treated with adjuvant durvalumab. Patients with PD-L1 expression < 1% may have limited benefit from adjuvant durvalumab.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Marc-Andre Leger, Bertrand Routy, Daniel Juneau
Summary: This article discusses the importance of strategies in clinical management of lung cancer patients over the past decade, particularly focusing on immunotherapy. It emphasizes the creation of novel standardized response criteria and the use of FDG PET/CT metrics to predict response to ICI therapy. Additionally, it mentions the potential immune-related adverse events associated with ICI therapy.
SEMINARS IN NUCLEAR MEDICINE
(2022)
Article
Oncology
Jihui Li, Shushan Ge, Shibiao Sang, Chunhong Hu, Shengming Deng
Summary: This study aimed to evaluate the expression of PD-L1 in NSCLC patients using radiomic features from F-18-FDG PET/CT images and clinicopathological characteristics. A prediction model combining radiomic signature and clinicopathologic features showed good predictive value in predicting PD-L1 expression levels above 1% and 50%.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Pathology
Lynette M. Sholl
Summary: Immunotherapy is crucial in the management of non-small cell lung carcinoma, but responses vary widely. PD-L1 protein expression serves as a predictive biomarker, yet its sensitivity and specificity are suboptimal. Insights into tumor and host immune-specific factors are defining better immunotherapy biomarkers beyond immune checkpoint expression status.
Article
Multidisciplinary Sciences
Kabsoo Shin, Joori Kim, Se Jun Park, Myung Ah Lee, Jae Myung Park, Myung-Gyu Choi, Donghoon Kang, Kyo Young Song, Han Hong Lee, Ho Seok Seo, Sung Hak Lee, Bohyun Kim, Okran Kim, Juyeon Park, Nahyeon Kang, In-Ho Kim
Summary: The study investigated the prognostic significance of soluble PD-L1 (sPD-L1) and exosomal PD-L1 (exoPD-L1) in patients with gastric cancer receiving chemotherapy. It was found that low levels of sPD-L1 and exoPD-L1 were associated with better overall survival and progression-free survival. Pretreatment sPD-L1 could be used as an independent prognostic factor for overall survival, while exoPD-L1 may reflect the immunosuppressive state of patients.
SCIENTIFIC REPORTS
(2023)
Article
Biotechnology & Applied Microbiology
Hao Zuo, Yihong Wan
Summary: This study demonstrates the important roles of programmed death-ligand 1 (PD-L1) in bone cell differentiation and cancer bone metastasis. The results show that PD-L1 antibody or PD-L1 deletion suppresses osteoclast differentiation and reduces bone metastases in breast cancer and melanoma. Transcriptional profiling reveals that PD-L1 deletion enhances immune-stimulatory genes, promotes macrophage M1 polarization, inhibits M2 polarization, boosts IFN gamma signaling, and increases T cell recruitment and activation.
CANCER GENE THERAPY
(2022)
Article
Oncology
Asuka Kawachi, Hiroshi Yoshida, Shigehisa Kitano, Yoshinori Ino, Tomoyasu Kato, Nobuyoshi Hiraoka
Review
Urology & Nephrology
Takayuki Nakayama, Shigehisa Kitano
INTERNATIONAL JOURNAL OF UROLOGY
(2019)
Article
Oncology
Takahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Satoru Iwasa, Kan Yonemori, Akihiko Shimomura, Shigehisa Kitano, Takafumi Koyama, Natsuko Sato, Kiyohiko Nakai, Michiyasu Inatani, Noboru Yamamoto
INVESTIGATIONAL NEW DRUGS
(2020)
Article
Dermatology
Yusuke Muto, Shigehisa Kitano, Arata Tsutsumida, Kenjiro Namikawa, Akira Takahashi, Yoshio Nakamura, Takeharu Yamanaka, Noboru Yamamoto, Naoya Yamazaki
JOURNAL OF DERMATOLOGY
(2019)
Article
Oncology
Koji Yoshino, Takayuki Nakayama, Ayumu Ito, Eiichi Sato, Shigehisa Kitano
Article
Hematology
Akihisa Kawajiri, Shigehisa Kitano, Akiko Miyagi Maeshima, Yoshihiro Inamoto, Kinuko Tajima, Tomonari Takemura, Takashi Tanaka, Ayumu Ito, Keiji Okinaka, Saiko Kurosawa, Sung-Won Kim, Hirokazu Taniguchi, Chitose Ogawa, Koji Izutsu, Noboru Yamamoto, Takahiro Fukuda
EUROPEAN JOURNAL OF HAEMATOLOGY
(2019)
Article
Hematology
Ayumu Ito, Shigehisa Kitano, Kinuko Tajima, Youngji Kim, Takashi Tanaka, Yoshihiro Inamoto, Sung-Won Kim, Noboru Yamamoto, Takahiro Fukuda, Shinichiro Okamoto
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2020)
Article
Oncology
Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, Kenichi Yoshimura, Katsuhisa Horimoto, Masashi Kitazawa, Kazuhiko Fukui, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Yoshitake Murayama, Kyoichi Kaira, Kunihiko Kobayashi
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Jun Sato, Shigehisa Kitano, Noriko Motoi, Yoshinori Ino, Noboru Yamamoto, Shunichi Watanabe, Yuichiro Ohe, Nobuyoshi Hiraoka
Article
Oncology
Hiroyasu Aoki, Satoshi Ueha, Shigeyuki Shichino, Haru Ogiwara, Kohei Shitara, Manami Shimomura, Toshihiro Suzuki, Tetsuya Nakatsura, Makiko Yamashita, Shigehisa Kitano, Sakiko Kuroda, Masashi Wakabayashi, Makoto Kurachi, Satoru Ito, Toshihiko Doi, Kouji Matsushima
Summary: Transient depletion of CD4(+) cells leads to replacement of T-cell clones in the blood, which is associated with the extent of CD4(+) T-cell depletion and an increase in CD8(+) T-cell count. This clonal replacement of the TCR repertoire is linked to the expansion of tumor-reactive T-cell clones and antitumor responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Daiki Ikarashi, Shigehisa Kitano, Takashi Tsuyukubo, Kazumasa Takenouchi, Takayuki Nakayama, Hiroko Onagi, Asumi Sakaguchi, Makiko Yamashita, Hidenori Mizugaki, Shigekatsu Maekawa, Renpei Kato, Yoichiro Kato, Tamotsu Sugai, Tetsuya Nakatsura, Wataru Obara
Summary: The study revealed that the response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with the density of CD8(+) T cells and CD204(+) cells in the tumor microenvironment, and that a higher density of CD204(+) cells is a poor prognostic factor for these patients.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto
Summary: This study reports the dose-escalation part of a phase I study of liposomal eribulin in Japanese patients with advanced solid tumors. The study found that liposomal eribulin was well tolerated at a dosage of 2.0 mg/m(2) once every three weeks and 1.5 mg/m(2) once every two weeks, and recommended a dosage of 2.0 mg/m(2) once every three weeks.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei Nukaya, Hideto Chono, Junichi Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku
Summary: This study investigated the use of T-cell receptor (TCR)-engineered T cells to treat patients with solid tumors expressing NY-ESO-1. The results showed significant tumor response and some patients experienced early-onset cytokine release syndrome (CRS). One patient developed severe lung injury associated with the TCR-T cell infusion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Shigehisa Kitano, Toshio Shimizu, Takafumi Koyama, Takahiro Ebata, Satoru Iwasa, Shunsuke Kondo, Akihiko Shimomura, Yutaka Fujiwara, Noboru Yamamoto, Anne Paccaly, Siyu Li, Petra Rietschel, Tasha Sims
Summary: This study assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. Results showed that cemiplimab exhibited antitumor activity in these patients with a comparable safety profile to other PD-1 inhibitors.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
